Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Tools & Techniques

New CRISPR case to finally settle the score

How the latest interference between Broad and UC could shake up the landscape of CRISPR therapies

Lauren Martz, Associate Editor
July 25, 2019 10:49 PM UTC

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter to drug developers.

The outcome is likely to shake up the IP rights of CRISPR companies, with the stakes highest for the most advanced biotechs whose therapies rely on CRISPR-Cas9, the foundational technology...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Broad Institute of Mit and Harvard

Toolgen Inc.

University of California Berkeley